Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
TriNetX Becomes the Most Cited Real-World Data Source in Peer-Reviewed Research
The findings highlight a sharp rise in the use of TriNetX data by clinical researchers, public health agencies, and healthcare organizations worldwide. With 2,025 citations, TriNetX is referenced nearly 1,300% more than its closest competitor with 149 citations, underscoring its growing role in powering real-world evidence generation. The findings highlight a sharp rise in the use of TriNetX data by clinical researchers, public health agencies, and healthcare organizations worldwide. With…
PR Newswire
15/10/2025
Novo Nordisk and Omeros announce asset purchase and license agreement for…
Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease portfolioOmeros is eligible to receive 340 million US dollars in upfront and near-term milestone payments, up to a total of 2.1 billion dollars including potential development and commercial milestones, plus tiered royalties on net salesBagsværd, Denmark and Seattle, US, 15 October 2025– Novo Nordisk and Omeros Corporation (Nasdaq: OMER) today announced...
Nasdaq GlobeNewswire
15/10/2025
Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with…
Collaboration and license agreement will advance Boehringer’s expanding antibody-drug conjugate (ADC) portfolio with a new asset expected to enter first-in-human studies next year .New, potentially best-in-class ADC is targeting a tumor selective marker present in a broad spectrum of cancers with high medical need. Ingelheim, Germany, and Seoul, Korea, 15 October 2025 –Boehringer Ingelheim and AimedBio, a biotechnology company specializing in the development of antibody-based...
Nasdaq GlobeNewswire
15/10/2025
Global Anti-Aging Industry Insights: Segmentation by Demographics and Product…
Transparency Market Research
15/10/2025
Endo Announces Peyronie's Disease Presentation at the North Central Section of…
The Endo-sponsored presentation is below: The Endo-sponsored presentation is below: About the StudyThis Phase 4 multicenter, noninterventional, retrospective study evaluated the effectiveness and safety of CCH in adult men with PD and ventral curvature (VC). Researchers reviewed medical charts of patients aged 18 and older diagnosed with VC and a palpable plaque, treated with CCH between 2014 and each site's study start date. The primary endpoint was percent change in penile VC, while...
PR Newswire
15/10/2025
Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1…
Under an investigator-initiated trial agreement, Tagworks and Radboudumc have initiated the first-in-human Phase 0/1 clinical development of TGW211 in a single center, open-label imaging study in patients with HER2-positive solid tumors. The primary objectives of the study are to determine safety and tolerability of Indium-111 (111In)-labeled TGW211, and secondary endpoints include evaluating the pharmacokinetics and dosimetry of 111In-TGW211 in tumor and healthy tissue. The study is currently…
PR Newswire
15/10/2025
Amphista Therapeutics nominates AMX-883, an orally available Targeted Glue™…
AMX-883 uses Amphista’s Targeted Glue™ technology, inducing degradation of BRD9 through the recruitment of DCAF16, a completely distinct mechanism of action from cereblon- or VHL-based PROTACs.The nomination of AMX-883 is underpinned by novel mechanistic insights and a compelling preclinical data package which establishes a pivotal role for BRD9 in acute myeloid leukaemia .As a broad-acting, pro-differentiation agent, AMX-883 acts independently of karyotype status and has the...
Nasdaq GlobeNewswire
15/10/2025
Digital Health Market Size to Worth USD 2688 Billion by 2035 at 22.55% CAGR |…
The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.vantagemarketresearch.com/digital-health-market-1297/request-sample The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.vantagemarketresearch.com/digital-health-market-1297/request-sample Free Sample Includes: Why This Market Matters to CXOs Technological & Industry Drivers: Strategic Insights...
PR Newswire
15/10/2025
Mission Therapeutics raises $13.3 million to progress first-in-class Parkinson's…
Dr Anker Lundemose, Executive Director at Mission Therapeutics, said: "Thanks to this additional $13.3m from our investors, we can now make the next vital steps progressing MTX325 into PD patients with this essential Phase 1b clinical trial. This will enable us to build upon the compelling preclinical data package for MTX325, published in Nature Communications in 2023, and the results from the Phase 1a studies that we have obtained." Dr Anker Lundemose, Executive Director at Mission...
PR Newswire
15/10/2025
Aignostics Launches AI-Powered Application for Tumor Microenvironment Profiling
Atlas H&E-TME was created using Atlas, the leading foundation model co-developed by Aignostics, Mayo Clinic, and Charité Berlin. It delivers detailed readouts for quality control, seven different tissue types, and nine different cell classes in addition to over 5,000 higher-order quantitative metrics per image. Atlas H&E-TME is available as a self-service application, with integrations to major image management systems coming soon. The application has been extensively validated across…
PR Newswire
15/10/2025
Sinocare Showcases Its Comprehensive Diabetes Management Solutions at EASD
On the opening Monday of EASD 2025 in Vienna, Professor Lori Laffel, Dr. Guido Freckmann, and Professor Julia Mader were invited to share their researches collaborated with iCanTM CGM. The symposium highlighted key themes 'Performance, Practicality, and Pediatrics,' and presented promising data from recent German and U.S. studies involving both adult and pediatric populations. Additionally, the session provided insights into initiating CGM systems in real-world settings, featuring expertise from…
PR Newswire
15/10/2025
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to…
A Registrational Phase 2 clinical trial has been initiated for 64Cu-PSMA-I&T - a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells 64 Cu-PSMA-I&T - a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells. 64 Cu-PSMA-I&T is being assessed as a diagnostic PET imaging agent labeled with the radioisotope Copper-64, being developed with its therapeutic pair,177...
Nasdaq GlobeNewswire
15/10/2025
Coway Named a Winner at the Good Design Awards 2025
SEOUL, South Korea , Oct. 15, 2025 /PRNewswire/ -- Coway Co., Ltd., the "Best Life Solution Company", is today proud to announce that it has been named a "Winner" at the Good Design Awards 2025. SEOUL, South Korea , Oct. 15, 2025 /PRNewswire/ -- Coway Co., Ltd., the "Best Life Solution Company", is today proud to announce that it has been named a "Winner" at the Good Design Awards 2025. Hosted by the Japan Institute of Design Promotion (JDP), the Good…
PR Newswire
15/10/2025
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, Oct.15, 2025(GLOBE NEWSWIRE) --Market: Euronext Paris / Nasdaq Euronext Compartment: BISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website:www.nanobiotix.comDate Number of Shares OutstandingTotal number of voting rightsTotal voting...
Nasdaq GlobeNewswire
15/10/2025
At the World Congress of Neurology, WHO Outlines a Global Roadmap to Make Brain…
"The science is clear and the path is practical," said Dr. Tarun Dua of the World Health Organization. "If countries embed brain health in universal coverage, strengthen primary care, ensure access to essential medicines, reduce stigma, and invest in data systems, we can measurably improve lives—especially in settings where the need is greatest." "The science is clear and the path is practical," said Dr.Tarun Duaof the World Health Organization. "If countries…
PR Newswire
15/10/2025
Anaplastic Astrocytoma Market is Predicted to Exhibit Remarkable Growth During…
Anaplastic Astrocytoma Market Summary Anaplastic Astrocytoma Market Summary Discover the anaplastic astrocytoma new treatment @New Treatments for Anaplastic Astrocytoma Key Factors Driving the Growth of the Anaplastic Astrocytoma Market Rising Anaplastic Astrocytoma Incidence and Aging Populations Anaplastic astrocytoma is a malignant brain tumor primarily affecting adults aged 40 and above. The increasing prevalence of brain tumors, including anaplastic astrocytoma,...
PR Newswire
14/10/2025
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial…
Attachments pdmr-notification-C-Ackermann-option exercise-oct 2025pdmr-notification-C-Ackermann-sale of shares-oct 2025
Nasdaq GlobeNewswire
14/10/2025
Inventiva Announces the Implementation of a New ATM Program
Daix (France), New York City (New York, United States), October 14, 2025 –Inventiva (Euronext Paris and Nasdaq : IVA) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) has filed today a shelf registration statement on Form F-3 (the “ Registration Statement ”) with the Securities and Exchange Commission (“ SEC ”). The Registration Statement...
Nasdaq GlobeNewswire
14/10/2025
GCC Medical Tourism Market to Reach USD 889.97 million by 2032, Growing At An…
The Gulf Cooperation Council (GCC) medical tourism sector is witnessing remarkable growth, positioning the region as a global hub for advanced healthcare services. The GCC Countries Medical Tourism Market is projected to expand from USD 367.41 million in 2024 to USD 889.97 million by 2032, reflecting a CAGR of 10.26% during 2024–2032. The Gulf Cooperation Council (GCC) medical tourism sector is witnessing remarkable growth, positioning the region as a global hub for advanced healthcare…
PR Newswire
14/10/2025
Spineway : Revenue growth in the third quarter
SPINEWAY Revenue growth in the third quarter In thousands of euros 20252024Change as a % Q3 revenue3,0452,575 +18%Q2 revenue2,7453,465-21% Q1 revenue2,8283,070-8%9M revenue8,6189,110 -5% Unaudited consolidated data The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, benefited, in line with its expectations, from a deferral of orders from major accounts to the third...
Nasdaq GlobeNewswire
14/10/2025
Sanofi: Information concerning the total number of voting rights and shares -…
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of theCode de commerce(the French Commercial Code) and article 223-16 of theRèglement général de l’Autorité des Marchés Financiers(Regulation of the French stock market authority) Sanofi a Frenchsociété anonymewith a registered share capital of €2,454,937,946 Registered office : 46, avenue de la Grande Armée - 75017 Paris - France Registered at the Paris...
Nasdaq GlobeNewswire
14/10/2025
THX PHARMA (THERANEXUS) AND EXELTIS ACHIEVE KEY MILESTONE TOWARDS THE…
THX PHARMA (THERANEXUS) AND EXELTIS ACHIEVE KEY MILESTONE TOWARDS THE COMMERCIALIZATION OF TX01 THX Pharma (Theranexus) and Exeltis have reached a pivotal milestone, setting the stage for the regulatory submission of TX01 for Gaucher and Niemann-Pick type C diseases Lyon, France – Madrid, Spain – October 14, 2025 – 6…
Actusnews Wire
14/10/2025
Sequana Medical alfapump® System Highlighted at SIR EDGE 2025 Conference
, Oct.14, 2025(GLOBE NEWSWIRE) --Ghent, Belgium – 14 October 2025–Sequana Medical NV (Euronext Brussels: SEQUA(the“Company”or“Sequana Medical” ), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announced that thealfa pump System was highlighted in a presentation at the Society of Interventional Radiology’s SIR EDGE 2025 conference in San Diego. The presentation titled “Not the Alpha Male, the Alfapump!” showcased...
Nasdaq GlobeNewswire
14/10/2025
Breast Fillers Market to Reach $728.7 million, Globally, by 2034 at 6.3% CAGR…
Breast fillers are gaining popularity due to their customizable results, fewer complications, and increasing demand for natural looking enhancements. Advancements in filler technology and growing aesthetic consciousness, particularly among younger women, are driving market growth globally. Breast fillers are gaining popularity due to their customizable results, fewer complications, and increasing demand for natural looking enhancements. Advancements in filler technology and growing aesthetic...
PR Newswire
14/10/2025
Altri Comunicati
